Expansion of the Clinical Testing Business Through New Projects and New Testing Items
First written in FY2017-Q1. 17 of 33 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「From January 2026, we began providing a “Biological Age Measurement Kit” based on the latest epigenetics research, which analyzes gene activity in cells in saliva to measure an individual’s biological age, or genetic age.」
In the clinical and mail-in testing businesses, a new service to measure biological age was launched in January 2026, expanding the test menu. - FY2026-H1AdvancedAnnual report
「As a new service related to personalized cancer medicine, we launched a “neoantigen detection service” that analyzes the genetic information of each patient’s cancer tissue and identifies neoantigens, which are unique markers.」
In clinical testing and personalized medicine, a new service was launched to identify neoantigens from genetic information in cancer tissue. - FY2025-H1RestatedAnnual report
「We will continue to proactively add new clinical testing services and expand the business.」
Reconfirming the policy of expanding the business by adding new tests to the clinical testing services, including WellMill, saliva testing and testing contract services for clinical trials. - FY2024AdvancedAnnual report
「In addition, in March 2024, we added a new test using saliva.」
In the clinical testing business, a new saliva-based test was added to the mail-in testing service “WellMill,” expanding the testing services. - FY2024-Q3RestatedAnnual report
「We launched COVID-19 PCR testing in March 2021 and have conducted a cumulative total of 330,000 tests, primarily for government agencies, medical institutions, companies and individuals.」
For the clinical testing business, reconfirming the cumulative 330,000 COVID-19 PCR tests conducted and the provision of testing to government agencies, medical institutions, companies and individuals. - FY2024-Q2RestatedAnnual report
「We launched COVID-19 PCR testing in March 2021 and have conducted a cumulative total of 330,000 tests, primarily for government agencies, medical institutions, companies and individuals.」
For the clinical testing business, reconfirming the cumulative 330,000 COVID-19 PCR tests conducted and the track record of providing testing to government agencies, medical institutions, companies and individuals. - FY2024-Q1AdvancedAnnual report
「In addition, drawing on our expertise in mail-in PCR testing, we launched a new mail-in testing service, “WellMill,” in April 2023. WellMill is a mail-in testing service that enables users to easily measure indicators such as “stress,” “menopause,” “male hormones” and “female hormones” at home.」
In the clinical testing business, the mail-in testing service “WellMill” was launched in April 2023. Cumulative COVID-19 PCR tests reached 330,000, and REPROCELL USA also entered into a contract in May 2023 with US-based Lantern Pharma for outsourced specimen processing and testing related to its Phase II clinical trial, expanding its testing services. - FY2023-Q3RestatedAnnual report
「We will continue to add new tests and expand the business.」
Reconfirming the policy of expanding the clinical testing business by adding new tests on the foundation of PCR testing, HLA-related testing and companion diagnostic services for cancer. - FY2023-Q2RestatedAnnual report
「In addition to determining whether a specimen is positive or negative, our PCR test can identify variants such as Omicron BA.5 in approximately 1–2 hours. Genome analysis is normally used to identify variants and takes approximately 2 days, whereas our test substantially reduces the time required for variant identification.」
For PCR testing, reconfirming the ability to identify variants in approximately 1–2 hours and the policy of expanding sales to medical institutions, companies and individuals. - FY2023-Q1AdvancedAnnual report
「In addition to determining whether a specimen is positive or negative, our PCR test can identify variants such as Omicron BA.5 in approximately 1–2 hours. Genome analysis is normally used to identify variants and takes approximately 2 days, whereas our test substantially reduces the time required for variant identification. We are currently expanding this test for medical institutions, companies and individuals, and, through a business partnership with Nippon Chouzai Co., Ltd., are selling it at the company’s Health Check Stations nationwide. We are also proceeding with sales through major e-commerce sites, including Amazon and Rakuten Ichiba.」
For PCR testing, the Company demonstrates the ability to identify variants such as Omicron BA.5 in approximately 1–2 hours and is expanding its sales channels beyond medical institutions, companies and individuals to Health Check Stations nationwide, Amazon and Rakuten Ichiba. - FY2022-Q3AdvancedAnnual report
「In addition to determining whether a specimen is positive or negative, our PCR test can identify multiple variants, including the Omicron and Delta variants, in approximately 1–2 hours. Genome analysis is normally used to identify variants and takes approximately 2 days, whereas our test substantially reduces the time required for variant identification. We are currently expanding this test for medical institutions, companies and individuals, and, through a business partnership with Nippon Chouzai Co., Ltd., are also proceeding with sales at the “Health Check Stations” operated by the company nationwide.」
For COVID-19 PCR testing, the Company demonstrates the ability to identify multiple variants, including the Omicron variant, in approximately 1–2 hours and is expanding its sales channels nationwide to Health Check Stations through its partnership with Nippon Chouzai. - FY2022-Q2AdvancedAnnual report
「In March 2021, we newly launched COVID-19 PCR testing. Using SmartAmp reagents for detecting variants, manufactured by Danaform Co., Ltd., we also simultaneously conduct identification testing for multiple variants in positive specimens, including the Delta variant originating in India, the Alpha variant originating in the UK and the Lambda variant originating in Peru. We are expanding this testing to individuals, companies and medical institutions.」
For COVID-19 PCR testing, the Company supports identification testing for multiple variants and is expanding its target customers to individuals, companies and medical institutions. - FY2022-Q1AdvancedAnnual report
「Since registering as a laboratory in 2005, we have provided clinical testing contract services related to organ transplantation and have a track record of transactions with more than 300 medical institutions throughout Japan. Our core tests are HLA typing and anti-HLA antibody testing related to immune rejection. In March 2021, we newly launched COVID-19 PCR testing. In addition, our Indian subsidiary newly launched non-invasive prenatal testing in March 2021. In April 2021, we also launched companion diagnostic services for cancer.」
In the clinical testing business, the Company has demonstrated a track record of transactions with more than 300 medical institutions throughout Japan, while expanding its test menu through the launch of COVID-19 PCR testing, non-invasive prenatal testing and companion diagnostic services for cancer. - FY2021AdvancedAnnual report
「In March 2021, we newly launched COVID-19 PCR testing. In addition, our Indian subsidiary newly launched non-invasive prenatal testing in March 2021.」
In the clinical testing business, COVID-19 PCR testing and non-invasive prenatal testing in India were launched in March 2021. - FY2021-Q3RestatedAnnual report
「In the medical business, in addition to these regenerative medicine services, we also provide clinical testing contract services related to organ transplantation. The Company’s core test, anti-HLA antibody testing after organ transplantation, was added to the national health insurance reimbursement schedule from 1 April 2018. The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」
Reconfirming the clinical testing contract services related to organ transplantation, the inclusion of anti-HLA antibody testing in the national health insurance reimbursement schedule, and the framework for operating as an accredited testing facility. - FY2021-Q2RestatedAnnual report
「In the medical business, in addition to these regenerative medicine services, we also provide clinical testing contract services related to organ transplantation. The Company’s core test, anti-HLA antibody testing after organ transplantation, was added to the national health insurance reimbursement schedule from 1 April 2018. The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」
Reconfirming the clinical testing contract services related to organ transplantation, the inclusion of anti-HLA antibody testing in the national health insurance reimbursement schedule, and the framework for operating as an accredited testing facility. - FY2021-Q1RestatedAnnual report
「The Company’s core test, anti-HLA antibody testing after organ transplantation, was added to the national health insurance reimbursement schedule from 1 April 2018. The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」
Reconfirming the inclusion of anti-HLA antibody testing in the national health insurance reimbursement schedule and the accreditation framework for organ transplantation-related testing. - FY2020RestatedAnnual report
「The Company’s registered laboratory has been accredited by the Japanese Society for Histocompatibility and Immunogenetics as an “Accredited Histocompatibility Testing Registered Facility.”」
Reconfirming the clinical testing contract services related to organ transplantation and the reimbursement coverage and accreditation framework for the Company’s core anti-HLA antibody testing. - FY2020-Q3RestatedAnnual report
「In addition to these regenerative medicine activities, our medical business also provides outsourced clinical testing services related to organ transplantation. Our core test, anti-HLA antibody testing after organ transplantation, became eligible for insurance coverage effective 1 April 2018.」
Reconfirming the clinical testing contract services related to organ transplantation and the inclusion of anti-HLA antibody testing in the national health insurance reimbursement schedule from 1 April 2018. - FY2020-Q2RestatedAnnual report
「In addition to these regenerative medicine activities, our medical business also provides outsourced clinical testing services related to organ transplantation. Our core test, anti-HLA antibody testing after organ transplantation, became eligible for insurance coverage effective 1 April 2018.」
Reconfirming the clinical testing contract services related to organ transplantation and the inclusion of anti-HLA antibody testing in the national health insurance reimbursement schedule. - FY2020-Q1RestatedAnnual report
「Our core test, anti-HLA antibody testing after organ transplantation, became eligible for insurance coverage effective 1 April 2018.」
We have reaffirmed the insurance coverage of our core anti-HLA antibody testing and the continued provision of outsourced clinical testing services related to organ transplantation. - FY2019-Q3RestatedAnnual report
「Effective 1 April 2018, our core tests, anti-HLA antibody screening and anti-HLA antibody antibody-specificity identification testing, became eligible for insurance coverage after all organ transplants.」
We have reaffirmed that our core anti-HLA antibody tests became eligible for insurance coverage for all post-organ-transplant testing and that the number of test requests is expected to increase following the new coverage. - FY2019-Q2RestatedAnnual report
「Effective 1 April 2018, our core tests, anti-HLA antibody screening and anti-HLA antibody antibody-specificity identification testing, became eligible for insurance coverage after all organ transplants.」
We have reaffirmed that our core anti-HLA antibody tests became eligible for insurance coverage for all post-organ-transplant testing and that the number of test requests is expected to increase going forward. - FY2019-Q1AdvancedAnnual report
「Finally, in clinical testing, anti-HLA antibody testing after organ transplantation was listed for insurance coverage effective 1 April 2018. We had already been receiving orders for anti-HLA antibody testing from medical institutions nationwide, and expect the number of tests to increase as a result of the new insurance coverage.」
Anti-HLA antibody testing became eligible for insurance coverage effective 1 April 2018, moving to the stage at which an increase in the number of tests is expected. - FY2018AdvancedAnnual report
「During the fiscal year, our core tests, anti-HLA antibody screening and anti-HLA antibody single-antigen identification testing, were listed for insurance coverage for testing after all organ transplants.」
In the clinical testing business, the 2 core tests were listed for insurance coverage as post-transplant tests for all organ transplants, representing institutional progress that supports an expansion in orders. - FY2018-Q3RestatedAnnual report
「We also provide outsourced clinical testing services related to organ transplantation.」
The disclosure states that outsourced clinical testing services related to organ transplantation continue, but does not indicate any new contract or launch of a new test item. - FY2018-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, we entered into a contract with Hitachi Chemical Co., Ltd. and launched a test for early detection of immune rejection after kidney transplantation using the ExoComplete research-use kit developed by the company, a kit for extracting mRNA from urinary exosomes. The test is called the Urinary Exosome Kidney Transplant Monitoring Test.」
Under the contract with Hitachi Chemical, we launched testing for immune rejection after kidney transplantation using urinary exosomes, bringing a new test item into actual service. - FY2017AdvancedAnnual report
「Going forward, we will work in coordination with the relevant academic societies to expand insurance coverage for the test.」
For expansion of the clinical testing business, we identified expanding insurance coverage in cooperation with relevant academic societies as a specific measure in addition to winning new projects. - FY2017-Q3AdvancedAnnual report
「During the third quarter of the fiscal year, we entered into a new contract with Helios for outsourced testing services related to clinical trials of regenerative medicine products. Going forward, we plan to conduct testing in stages according to the progress of clinical trials conducted by Helios.」
In the clinical testing business, we newly entered into a contract for outsourced testing services related to clinical trials of regenerative medicine products. - FY2017-Q2AdvancedAnnual report
「With anti-HLA antibody testing, including screening and single-antigen identification testing, as our core offering, we receive testing orders from more than 100 hospitals nationwide in Japan. While continuing to accept requests from existing customers, we are actively pursuing new projects and launching new test items.」
We have a track record of receiving orders from more than 100 hospitals nationwide and continue to pursue new projects and new test items. - FY2017-Q1First statedAnnual report
「We are currently actively pursuing activities to win new large-scale projects and launch new test items.」
With anti-HLA antibody testing as our core offering, we are pursuing new large-scale projects and expanding our test menu.